CN113546129A - New use of Bulbus Allii Macrostemi extract - Google Patents
New use of Bulbus Allii Macrostemi extract Download PDFInfo
- Publication number
- CN113546129A CN113546129A CN202110967684.2A CN202110967684A CN113546129A CN 113546129 A CN113546129 A CN 113546129A CN 202110967684 A CN202110967684 A CN 202110967684A CN 113546129 A CN113546129 A CN 113546129A
- Authority
- CN
- China
- Prior art keywords
- hair
- extract
- allium macrostemon
- alopecia
- bulbus allii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of pharmacy, in particular to an application of an allium macrostemon extract in preparing a medicament or a cosmetic for preventing and treating alopecia, wherein the allium macrostemon extract is prepared by the following method: pulverizing 500g of Bulbus Allii Macrostemi, extracting with 95% ethanol for 2 times by reflux extraction method, wherein the material-liquid ratio is 1:10 and 1:8 respectively; the extraction time is 2h and 1.5h respectively; the two filtrates are combined, concentrated and dried under reduced pressure.
Description
Technical Field
The invention belongs to the field of medicine. In particular to the application of the longstamen onion bulb extract in preparing the medicine or the cosmetics for preventing or treating alopecia and promoting hair growth.
Background
Alopecia has a significant impact on the mental health and quality of life of an individual, and is a source of low self-esteem and anxiety in many patients, and serious people can cause depression. Normally shed hair is typically hair in the catagen and telogen phases, and the normal amount of hair is maintained because the hair entering the catagen phase is constantly in dynamic balance with the hair entering the catagen phase. The pathological alopecia refers to abnormal or excessive hair loss, and the factors causing the pathological alopecia comprise heredity, mental stress, autoimmunity, acute and chronic infectious diseases, various skin diseases, endocrine dyscrasia, chemotherapy toxic and side effects and the like. Androgenetic alopecias (AGA), also known as seborrheic alopecia, belong to pathological alopecia, account for more than 90% of alopecia population, are mainly manifested by greasy scalp, pruritus, dandruff, alopecia and the like, are the most common clinical alopecia types, are caused by endocrine dyscrasia, are different from chemotherapy toxic and side effects, are mostly seen in young and old males between 20 and 30 years old, are characterized by progressive reduction of head and top hairs, mostly appear in adolescence, and aggravate with age. Androgenic alopecia is present in both males and females, but is more common in males. To date, the U.S. FDA has approved only two drugs for the treatment of androgenetic alopecia: the minoxidil tincture suitable for men and women and the oral finasteride tablet suitable for men only have obvious side effects, and the minoxidil tincture and the oral finasteride tablet are easy to relapse after stopping taking medicines.
Bulbus Allii Macrostemi (Alliiimacharostomunisbulb) is dried bulb of Bulbus Allii Macrostemi or Bulbus Allii Macrostemi of Liliaceae. The Bulbus Allii Macrostemi is a Chinese medicinal material with homology of medicine and food, and has effects of inhibiting blood platelet aggregation, reducing blood lipid, resisting atherosclerosis, inhibiting tumor, diminishing inflammation, resisting oxidation and inhibiting bacteria. The allium macrostemon has small toxic and side effects and is easy to plant, thus being a Chinese medicinal material with great development value.
Disclosure of Invention
The invention aims to provide a new application of a traditional Chinese medicine allium macrostemon extract.
Specifically, the invention provides an application of an allium macrostemon extract in preparing a medicine or a cosmetic for preventing and treating alopecia, wherein the allium macrostemon extract is prepared by the following method: pulverizing 500g of Bulbus Allii Macrostemi, extracting with 95% ethanol for 2 times by reflux extraction method, wherein the material-liquid ratio is 1:10 and 1:8 respectively; the extraction time is 2h and 1.5h respectively; the two filtrates are combined, concentrated and dried under reduced pressure.
In a preferred embodiment, the allium macrostemon extract is used as the only active ingredient for preparing the medicine or the cosmetic for preventing and treating the alopecia.
In another preferred embodiment, the alopecia is androgenetic alopecia.
The details of various aspects of the invention are set forth in subsequent sections. The features, objects, and advantages of the invention will be apparent from the description and from the claims.
Drawings
FIG. 1 shows the identification result of Chinese medicinal materials of Bulbus Allii Macrostemi
The Chinese medicinal materials of the allium macrostemon, the allium macrostemon reference substance and the allium macrostemon extract
Detailed Description
The invention arose in part from the unexpected discovery that: the allium macrostemon extract can promote the hair growth of a mouse model with androgenetic alopecia induced by testosterone. Therefore, the allium macrostemon extract can be used for preparing medicaments, health-care products, cosmetics, washing and caring products and the like for preventing and treating alopecia, particularly androgenetic alopecia.
Furthermore, the invention provides the application of the allium macrostemon extract in preparing the medicines or the cosmetics for preventing and treating the androgenetic alopecia.
The allium macrostemon extract can be prepared by the conventional method in the field, for example, the allium macrostemon Chinese medicinal material is crushed, the reflux extraction method is adopted to add 95 percent ethanol for extraction, the filtrate is combined, and the decompression, concentration and drying are carried out.
The medicinal carrier in the composition does not damage the pharmaceutical activity of the allium macrostemon extract, and the effective dosage of the allium macrostemon extract is nontoxic to human bodies when the dosage of the allium macrostemon extract plays a role of the medicinal carrier.
Such pharmaceutically acceptable carriers include, but are not limited to: lecithin, aluminum stearate, alumina, ion exchange materials, self-emulsifying drug delivery systems, tweens or other surfactants, serum proteins, buffer substances such as phosphates, glycine, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, mixtures of saturated fatty acid partial glycerides, and the like.
Other conventional pharmaceutical adjuvants such as binder (e.g. microcrystalline cellulose), filler (e.g. starch, glucose, anhydrous lactose and lactose beads), disintegrant (e.g. crosslinked PVP, croscarmellose sodium, low-substituted hydroxypropylcellulose), lubricant (e.g. magnesium stearate), and absorption enhancer, adsorption carrier, flavoring agent, sweetening agent, excipient, diluent, wetting agent, etc.
The allium macrostemon extract composition is prepared into medicines, cosmetics, washing care products and the like according to a conventional method in the field.
The cosmetic or hair care composition may be in the form of hair tonic, hair conditioner, hair essence, hair lotion, hair tonic lotion, shampoo, hair rinse, hair cream, hair tonic, hair massage cream, hair wax, hair gas, hair spray, hair pack, hair tonic, hair soap, hair cleansing foam, hair oil, hair drying agent, hair conditioner, hair dye, hair curling preparation, hair bleach, hair gel, hair glaze, hair dressing, hair tonic, hair moisturizer, hair mousse, and hair spray.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All the features disclosed in this specification may be combined in any combination and each feature disclosed in this specification may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
Example one
1. Experimental Material
1.1 medicinal materials
Testosterone (CAS: 58-22-0, molecular weight 288.42, HPLC purity 98% or more, Sigma-Aldrich Co.); minoxidil (CAS: 38304-91-5, HPLC purity is not less than 98%, Shanghai-sourced leaf Biotech limited); allium macrostemon traditional Chinese medicinal materials (Shanghai source leaf biotechnology limited); bulbus Allii Macrostemi traditional Chinese medicine reference (China food and drug testing research institute, batch No. 121130-202107)
1.2 Experimental animals
C57BL/6 male mice weighing 20 ± 2g (8 weeks), provided by the experimental animals center of the university of medicine in shanghai, animal certification No.: SYXK (Shanghai) 2009-0069. Placing in conventional breeding environment, and freely taking food and drinking water.
2. Experimental methods
2.1 preparation of Allium macrostemon extract
(1) Preparing the allium macrostemon extract powder: pulverizing 500g of Bulbus Allii Macrostemi, extracting with 95% ethanol for 2 times by reflux extraction method, wherein the material-liquid ratio is 1:10 and 1:8 respectively; the extraction time is 2h and 1.5h respectively; mixing the two filtrates, concentrating under reduced pressure, drying to obtain dry extract, pulverizing, and sieving to obtain 50g of Bulbus Allii Macrostemi extract powder.
(2) Adding 3g of Bulbus Allii Macrostemi extract powder into 100ml of 1, 2-propylene glycol, stirring and mixing to obtain 3% Bulbus Allii Macrostemi extract solution.
2.2 identification of Chinese medicine of longstamen onion bulb
The identification of the allium macrostemon traditional Chinese medicinal material is carried out according to the method of China pharmacopoeia of 2020, and allium macrostemon medicinal material powder and allium macrostemon extract powder are taken, 20ml of normal hexane is added, ultrasonic treatment is carried out for 20min, filtration is carried out, the filtrate is volatilized to dryness, and 1ml of normal hexane is added to residues for dissolution, so that the residues are used as a test solution. Preparing reference medicinal material of Bulbus Allii Macrostemi 4g, and making reference medicinal solution in the same way. Performing thin layer chromatography (general rule 0502) test, sucking 10ul of the above three solutions, respectively dropping on the same silica gel G thin layer plate, developing with n-hexane-ethyl acetate (10:1) as developing agent, taking out, air drying, spraying 10% sulphuric acid ethanol solution, heating at 105 deg.C until the spots are clearly developed, and inspecting under ultraviolet lamp (365 nm).
2.3 establishment and group sampling of androgenetic alopecia mouse model
A reference document for establishing an androgenetic alopecia mouse model (preliminary research on the hair growth influence of chickpea A on a pathological alopecia model mouse, natural product research and development: 2014,26: 613-618). A C57BL/6 male mouse (20 +/-2 g) with uniform weight is selected to be adaptively raised for 1 week, is mixed with rosin and paraffin, is heated, dissolved and cooled, is coated on the back of the mouse to remove hair, and induces the hair follicle of the mouse to enter a growth phase from a resting phase, wherein the hair follicle is not different from the spontaneously formed hair follicle in the growth phase in morphology, and the skin is pink. The experimental area on the back of each group of mice on the next day of hair removal was divided into groups and smeared according to the following method:
blank control group: smearing the solvent for 30min, and smearing blank matrix;
model group: coating 0.1% testosterone for 30min, and coating blank matrix;
minoxidil group: applying 0.1% testosterone for 30min, and applying 3% minoxidil solution (prepared with 1,2 propylene glycol);
allium macrostemon extract group: applying 0.1% testosterone for 30min, and applying 3% Bulbus Allii Macrostemi extract solution (preparation method is shown in 2.1);
2.4 evaluation index
2.4.1 Hair Length measurement
The hair was plucked out before, during and after the depilatory area at 15d, 18d and 21d, respectively, and the lengths thereof were measured and averaged.
2.4.2 gross weight measurement
After day 21, the mice were sacrificed and 3 x 3cm area of hair was cut along the hair roots in the depilated area, weighed on an analytical balance and averaged.
2.5 statistical analysis
All experimental data were repeated 3 times, the results were expressed as mean ± standard deviation, and One-way analysis of variance (One-way ANOVA) and LSD test were performed on the experimental data using SPSS 16.0 statistical software, with P <0.05 being statistically significantly different.
3. Results
3.1 identification of Chinese medicine of longstamen onion bulb
FIG. 1 shows that in the chromatogram of the test sample, the Chinese medicinal material of Bulbus Allii Macrostemi and the contrast of Bulbus Allii Macrostemi have fluorescent spots with the same color at the corresponding positions of the chromatogram; the allium macrostemon extract, the allium macrostemon traditional Chinese medicinal material and the allium macrostemon reference substance also have similar fluorescent spots on the corresponding positions of the chromatogram, but the fluorescence intensity is slightly low, thereby proving that the traditional Chinese medicinal material is the allium macrostemon.
3.2 therapeutic Effect of Allium macrostemon extract on mice with androgen alopecia induced by Testosterone
3.2.1 Effect of Allium macrostemon extract on Hair growth
Table 1 shows the effect of allium macrostemon extract on hair length. The hair lengths of the modeling days 15, 18 and 21 are selected for analysis, the hair growth of the blank control group is more, and the difference is significant (P is less than 0.001) compared with that of the alopecia model group, which shows that testosterone can inhibit the hair growth, and the model is successfully established; the minoxidil and the allium macrostemon extract can promote the hair growth, and the hair growth is remarkably different from the hair loss model group on 15 th, 18 th and 21 th days of the model building (P is less than 0.05 or P is less than 0.01 or P is less than 0.001). The above shows that the allium macrostemon extract can stimulate the growth of hair.
TABLE 1
3.2.2 Effect of Allium macrostemon extract on Hair weight
Table 2 shows the effect of allium macrostemon extract on the gross weight of mice. The mice are sacrificed on the 21 st day, a depilation area is selected, hairs with the area of 2 x 2cm are cut off, the blank control group is weighed by an analytical balance, the hair weight of the hair loss model group is 10.08 +/-3.64 mg, the minoxidil group is 63.35 +/-7.42 mg, and the allium macrostemon extract group is 36.2 +/-5.31 mg, so that the hair growth can be promoted by the minoxidil and the allium macrostemon extract. Compared with the hair loss model group, the hair weights of the minoxidil group and the allium macrostemon extract have significant difference (P is less than 0.01 or P is less than 0.001). The above shows that the allium macrostemon extract can stimulate the growth of hair.
TABLE 2
The results of the research show that the allium macrostemon extract can stimulate hair growth and treat androgenetic alopecia.
The various aspects of the invention are addressed above. It should be understood, however, that equivalent changes and modifications may be made thereto by those skilled in the art without departing from the spirit of the present invention, and that such changes and modifications are intended to be covered by the appended claims.
Claims (3)
1. The application of the allium macrostemon extract in preparing the drugs or cosmetics for preventing and treating alopecia is characterized in that the allium macrostemon extract is prepared by the following method: pulverizing 500g of Bulbus Allii Macrostemi, extracting with 95% ethanol for 2 times by reflux extraction method, wherein the material-liquid ratio is 1:10 and 1:8 respectively; the extraction time is 2h and 1.5h respectively; the two filtrates are combined, concentrated and dried under reduced pressure.
2. The use according to claim 1, characterized in that the allium macrostemon extract is used as the sole active ingredient for the preparation of a medicament or cosmetic for the prevention and treatment of alopecia.
3. Use according to claim 1 or 2, characterized in that the alopecia is androgenetic alopecia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110967684.2A CN113546129A (en) | 2021-08-23 | 2021-08-23 | New use of Bulbus Allii Macrostemi extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110967684.2A CN113546129A (en) | 2021-08-23 | 2021-08-23 | New use of Bulbus Allii Macrostemi extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113546129A true CN113546129A (en) | 2021-10-26 |
Family
ID=78134156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110967684.2A Pending CN113546129A (en) | 2021-08-23 | 2021-08-23 | New use of Bulbus Allii Macrostemi extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113546129A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173693A (en) * | 2014-06-30 | 2014-12-03 | 王统述 | Traditional Chinese medicinal composition for treating alopecia seborrhoeica |
-
2021
- 2021-08-23 CN CN202110967684.2A patent/CN113546129A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173693A (en) * | 2014-06-30 | 2014-12-03 | 王统述 | Traditional Chinese medicinal composition for treating alopecia seborrhoeica |
Non-Patent Citations (5)
| Title |
|---|
| 徐世前等: "无臭蒜素护肤霜及护发素的制备", 《适用技术之窗》, no. 2, 31 December 2000 (2000-12-31), pages 10 * |
| 斯琴: "小根蒜的氨基酸的成分测定", 《中国民族民间医药》, vol. 89, no. 06, 15 December 2007 (2007-12-15), pages 352 - 353 * |
| 潘飞等: "藠头皮中蒜素的提取工艺研究", 《中国调味品》, vol. 36, no. 12, 10 December 2011 (2011-12-10), pages 52 - 55 * |
| 王苗等: "中药薤白药食同源功效探析", 《亚太传统医药》, vol. 16, no. 06, 5 June 2020 (2020-06-05), pages 195 - 201 * |
| 罗梅梅: "朱其杰教授治疗雄激素性脱发中医用药规律研究", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》, 15 October 2012 (2012-10-15), pages 9 - 12 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6447762B1 (en) | Hair lotion useful for treatment of hair loss and stimulating hair growth | |
| EP1720515A1 (en) | Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia | |
| JP2013532720A (en) | Hair growth stimulation method | |
| JPH06128125A (en) | Hair tonic | |
| CN113546129A (en) | New use of Bulbus Allii Macrostemi extract | |
| CN108272781A (en) | Application of the soybean in the drug for preparing prevention alopecia | |
| JPH0853327A (en) | Hair tonic composed of allantoin or its derivative | |
| US20070116658A1 (en) | Hair tonic composition | |
| CN112915176B (en) | Alpinia katsumadai composition for preventing and treating alopecia | |
| WO2020111047A1 (en) | Composition for scalp and hair | |
| CN113041246A (en) | Curcumin composition for preventing and treating alopecia | |
| EP1317239B1 (en) | Synergetic combinations based on plants for treating hair loss | |
| CN109044996B (en) | Medical application of schisandrin | |
| RU2799324C2 (en) | Olespedea captic extract for hair care applications | |
| CN112494488B (en) | Application of rebamipide in preventing alopecia and growing hair | |
| EP3511006A1 (en) | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient | |
| KR100651023B1 (en) | Composition for improving hair growth comprising an non-polar solvent-soluble extract of Cantharis as an active ingredient | |
| JP2024513472A (en) | Hair serums and supplements | |
| JP3496896B2 (en) | Hair restorer and hair cosmetic | |
| KR20090059230A (en) | Cosmetic composition for anti-alopecia and trichogenousness | |
| CA2540725A1 (en) | Stimulation of hair growth by ginkgo biloba flavonoids | |
| WO1996001632A1 (en) | Method and compound for the treatment of hair loss | |
| KR20230047623A (en) | Composition for Prevention of Hair Loss and Promotion of Hair Growth in Nanoliposomes with Excellent Percutaneous Absorption | |
| JP2001354526A (en) | Hair restoration or hair tonic | |
| US20050180940A1 (en) | Protect against hair loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211026 |
|
| WD01 | Invention patent application deemed withdrawn after publication |